Olaratumab is no longer marketed in the United States. No information is available on the clinical use of olaratumab during breastfeeding. Because olaratumab is a large protein molecule with a molecular weight of about 154,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] However, olaratumab is given with doxorubicin. The manufacturer recommends that women should not breastfeed during treatment with olaratumab and for 3 months following the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
2.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Olaratumab
CAS Registry Number
1024603-93-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
